Trials / Terminated
TerminatedNCT00250861
Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma
A Randomized Phase II Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for CD20 Positive Aggressive Non-Hodgkin's Lymphoma Following High Dose Therapy With Autologous PBSC Rescue
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (planned)
- Sponsor
- US Oncology Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this research study is to find out if treatment with rituximab in combination with aldesleukin (compared to rituximab alone) decreases the risk of cancer returning, as well as determining what other effects (good and bad) this drug combination has on NHL. Rituximab and aldesleukin are not approved in combination by the Food and Drug Administration (FDA) for the treatment of non-Hodgkins lymphoma; however, Rituximab is approved for use by itself to treat NHL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab | |
| DRUG | Aldesleukin |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2005-11-08
- Last updated
- 2008-04-21
Locations
21 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00250861. Inclusion in this directory is not an endorsement.